Strides Pharma Science Limited
http://www.strides.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Strides Pharma Science Limited
BIOSECURE Act Diluted Significantly, But China Plus Strategy Still Accelerating: Strides MD
A time extension to US companies to shift business away from a few Chinese firms under the proposed BIOSECURE Act has disappointed the Strides MD. However, the China plus strategy continues to drive business and capacity expansion for auto-injectors required by GLP-1 customers is expected
Lupin CEO Highlights Structural Support For Generics Pricing, Sees gMyrbetriq Relaunch
Lupin’s CEO spoke of US drug shortages having led to recognition of the need for structural and regulatory support for viable pricing of generic drugs. She was also optimistic on the relaunch of a Myrbetriq generic after Astellas obtained a temporary restraining order against Lupin and Zydus just a few days post an at-risk launch by the latter two companies
No 'Constraining Situation' On Generic Vascepa API, Says Strides MD
Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business.
No “Constraining Situation” On gVascepa API Says Strides MD, Q3 Revenues Jump
Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Strides Arcolab Ltd.
- Strides Arcolab Limited
- Amneal Pharmaceuticals Pty Limited, Australia
- Faglis Medica Private Limited
- Strides Shasun Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice